{"page_content": "6\nESG R eport 2022\nFinancial Performance\nOur strong balance sheet \nenables focused execution on our \nnear- and long-term priorities \nadvancing genetically defined \ndisease therapies.\nIn April 2021, Agios divested its \noncology business for an upfront \npayment of $1.8 billion in order to \nfocus solely on accelerating and \nexpanding its genetically defined \ndisease portfolio. We invest in ongoing innovation on behalf of \npeople who have few or no treatment options. \n5-YEAR R&D INVESTMENT\n$1.4 billion2021 R&D INVESTMENT\n$298.5 million\nCASH POSITION\n$1.3 billion  \nas of Dec. 31, 2021", "metadata": {"source": "NASDAQ_AGIO_2021.pdf", "page": 5, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}